21,629 Shares in Immunome, Inc. (NASDAQ:IMNM) Bought by Profund Advisors LLC

Profund Advisors LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 21,629 shares of the company’s stock, valued at approximately $262,000.

Other institutional investors have also added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in shares of Immunome in the 2nd quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome in the second quarter worth $97,000. Arizona State Retirement System lifted its stake in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after buying an additional 918 shares during the period. EntryPoint Capital LLC grew its holdings in shares of Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after buying an additional 5,466 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Immunome in the 2nd quarter valued at $206,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Up 0.3 %

Shares of IMNM opened at $14.38 on Friday. The stock’s 50-day moving average price is $14.58 and its 200-day moving average price is $15.77. The company has a market capitalization of $862.35 million, a price-to-earnings ratio of -1.90 and a beta of 1.77. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The firm had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. As a group, equities analysts anticipate that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now owns 16,000 shares in the company, valued at $222,880. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Jean Jacques Bienaime purchased 7,000 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at $231,613.10. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jack Higgins sold 3,524 shares of the company’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The disclosure for this sale can be found here. 8.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Piper Sandler dropped their price target on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $29.00.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.